GV20 Therapeutics, established in 2016 with locations in Cambridge, USA, and Shanghai, China, is at the forefront of cancer immunology research. Leveraging high-throughput functional genomics and artificial intelligence (AI) methodologies, the company identifies novel drug targets in cancer immunology and develops effective antibody drugs. Through its proprietary antibody drug discovery engine, GV20 has built a robust portfoli...
GV20 Therapeutics, established in 2016 with locations in Cambridge, USA, and Shanghai, China, is at the forefront of cancer immunology research. Leveraging high-throughput functional genomics and artificial intelligence (AI) methodologies, the company identifies novel drug targets in cancer immunology and develops effective antibody drugs. Through its proprietary antibody drug discovery engine, GV20 has built a robust portfolio of immuno-oncology antibody drug candidates for cancer treatment.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.